Tetsuro Kubota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tetsuro Kubota has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Masahiko Watanabe
Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku‐ku, Tokyo 160–8582
5 shared publicationsMasaki Kitajima
Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku‐ku, Tokyo 160–8582
4 shared publicationsHirotoshi Hasegawa
Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku‐ku, Tokyo 160–8582
3 shared publicationsToshiharu Furukawa
3 shared publicationsYoshihide Otani
Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Sinjuku‐ku, Tokyo 160–8582
3 shared publicationsKoichiro Kumai
2 shared publications
Latest Publications
- 10 July 2008
- Vol. 22 (3) , 273-8
New chemotherapy strategies for gastric cancer.
Gastric cancer chemotherapy has entered a new era with the introduction of new drugs such as S-1, irinotecan (CPT-11), paclitaxel and docetaxel. Recent phase III studies have indicated that S-1 monotherapy, a remnant reference arm from a previous study, was not inferior to 5-FU alone, and that the combination of S-1 with cisplatin and CPT-11 showed higher efficacy than S-1 alone with tolerable side-effects for advanced and recurrent gastric cancer. In the adjuvant setting, S-1 monotherapy prolonged survival following surgery compared with surgery alone after curative extended (D2) lymph-node dissection for stage II/III gastric cancer. However, some issues remain, such as the sequence of several duplet chemotherapies, treatment following cases of S-1 failure, the relative efficacy of doublet and triplet therapies, and the impact of molecular-targeting.
- 10 July 2008
- Vol. 22 (3) , 273-8
New chemotherapy strategies for gastric cancer.
Gastric cancer chemotherapy has entered a new era with the introduction of new drugs such as S-1, irinotecan (CPT-11), paclitaxel and docetaxel. Recent phase III studies have indicated that S-1 monotherapy, a remnant reference arm from a previous study, was not inferior to 5-FU alone, and that the combination of S-1 with cisplatin and CPT-11 showed higher efficacy than S-1 alone with tolerable side-effects for advanced and recurrent gastric cancer. In the adjuvant setting, S-1 monotherapy prolonged survival following surgery compared with surgery alone after curative extended (D2) lymph-node dissection for stage II/III gastric cancer. However, some issues remain, such as the sequence of several duplet chemotherapies, treatment following cases of S-1 failure, the relative efficacy of doublet and triplet therapies, and the impact of molecular-targeting.
- Open Access
- 25 March 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (8) , 1301-1304
The role of S-1 in the treatment of gastric cancer
S-1 is a potent antitumour drug in gastric cancer. After years of disagreement about the utility of chemotherapy for advanced gastric cancer, several studies have recently demonstrated the efficacy of S-1 in both the adjuvant and primary settings. In this Minireview, the value of S-1 in the treatment of gastric cancer is discussed.
- 25 March 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (8) , 1301-1304
Open AccessThe role of S-1 in the treatment of gastric cancer
S-1 is a potent antitumour drug in gastric cancer. After years of disagreement about the utility of chemotherapy for advanced gastric cancer, several studies have recently demonstrated the efficacy of S-1 in both the adjuvant and primary settings. In this Minireview, the value of S-1 in the treatment of gastric cancer is discussed.
- 7 July 2006
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 11 (3) , 184-189
Gastrointestinal stromal tumor (GIST) and imatinib
Imatinib mesylate is the first and only effective drug for the treatment of gastrointestinal stromal tumor at present. Mutated exon 11 of the KIT receptor is essential for the pathogenesis and response to imatinib mesylate of gastrointestinal stromal tumor; the efficacy rate (complete response + partial response) of imatinib mesylate is 53.8%, and the disease-control rate (complete response + partial response + stable disease) is 84%. Almost 90% of patients experienced non-hematological and hematological adverse effects, which were tolerable, in particular at a daily dose of 400 mg imatinib mesylate, which warranted response induction for half of the patients, and is the dose approved by Japanese medical insurance. Clinical trials suggest that an increased dose of imatinib mesylate would be beneficial, and that the interruption of imatinib treatment might result in disease progression even after a partial response. Tentative Japanese guidelines for the diagnosis and therapy of gastrointestinal stromal tumors are being prepared by the Gastrointestinal Stromal Tumor Committee of the Japan Society of Clinical Oncology, and are presented here for critical comments by colleagues.
- 7 July 2006
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 11 (3) , 184-189
Gastrointestinal stromal tumor (GIST) and imatinib
Imatinib mesylate is the first and only effective drug for the treatment of gastrointestinal stromal tumor at present. Mutated exon 11 of the KIT receptor is essential for the pathogenesis and response to imatinib mesylate of gastrointestinal stromal tumor; the efficacy rate (complete response + partial response) of imatinib mesylate is 53.8%, and the disease-control rate (complete response + partial response + stable disease) is 84%. Almost 90% of patients experienced non-hematological and hematological adverse effects, which were tolerable, in particular at a daily dose of 400 mg imatinib mesylate, which warranted response induction for half of the patients, and is the dose approved by Japanese medical insurance. Clinical trials suggest that an increased dose of imatinib mesylate would be beneficial, and that the interruption of imatinib treatment might result in disease progression even after a partial response. Tentative Japanese guidelines for the diagnosis and therapy of gastrointestinal stromal tumors are being prepared by the Gastrointestinal Stromal Tumor Committee of the Japan Society of Clinical Oncology, and are presented here for critical comments by colleagues.
- Open Access
- 1 July 2003
- Published by Wiley in Cancer Science
- Vol. 94 (7) , 633-638
Gene expression in colorectal cancer and in vitro chemosensitivity to 5‐fluorouracil: A study of 88 surgical specimens
To predict the sensitivity of colorectal cancer to 5‐fluorouracil (5‐FU), we compared the gene expression of surgically obtained colorectal cancer specimens with chemosensitivity to 5‐FU as detected by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl‐2H tetrazolium bromide (MTT) assay. Eighty‐eight patients with advanced and/or metastatic colorectal cancer provided written informed consent and entered the trial from September 2000 to October 2001. Fresh surgical specimens were used for the MTT assay, and sensitivity to 5‐FU was evaluated at a cutoff concentration of 50 μg/ml and 48‐h incubation time. Frozen samples were stored at −80°C until mRNA analysis of thymidylate synthetase (TS), dihydropyri‐midine dehydrogenase (DPD), thymidine phosphorylase (TP), es‐nucleoside transporter (NT), and E2F1 by real‐time RT‐PCR. The correlations between the variables were analyzed, and the predictive value of these mRNAs was assessed statistically using a receiver operating characteristic (ROC) curve. NT and DPD, TP and DPD, and TP and NT mRNA expression levels correlated significantly, while TS and E2F1 showed no correlations. High NT expression was associated with low sensitivity to 5‐FU (PPP<0.034), although high TS mRNA expression did not. ROC curves indicated that DPD and NT mRNAs were possible predictors of sensitivity to 5‐FU, with cutoff values of 0.6 and 0.4, respectively. The sensitivity of colorectal cancer to 5‐FU may be regulated by DPD, the rate‐limiting enzyme of catabolism, and NT, an important transmembrane transporter of nucleosides.
- 1 July 2003
- Published by Wiley in Cancer Science
- Vol. 94 (7) , 633-638
Open AccessGene expression in colorectal cancer and in vitro chemosensitivity to 5‐fluorouracil: A study of 88 surgical specimens
To predict the sensitivity of colorectal cancer to 5‐fluorouracil (5‐FU), we compared the gene expression of surgically obtained colorectal cancer specimens with chemosensitivity to 5‐FU as detected by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl‐2H tetrazolium bromide (MTT) assay. Eighty‐eight patients with advanced and/or metastatic colorectal cancer provided written informed consent and entered the trial from September 2000 to October 2001. Fresh surgical specimens were used for the MTT assay, and sensitivity to 5‐FU was evaluated at a cutoff concentration of 50 μg/ml and 48‐h incubation time. Frozen samples were stored at −80°C until mRNA analysis of thymidylate synthetase (TS), dihydropyri‐midine dehydrogenase (DPD), thymidine phosphorylase (TP), es‐nucleoside transporter (NT), and E2F1 by real‐time RT‐PCR. The correlations between the variables were analyzed, and the predictive value of these mRNAs was assessed statistically using a receiver operating characteristic (ROC) curve. NT and DPD, TP and DPD, and TP and NT mRNA expression levels correlated significantly, while TS and E2F1 showed no correlations. High NT expression was associated with low sensitivity to 5‐FU (PPP<0.034), although high TS mRNA expression did not. ROC curves indicated that DPD and NT mRNAs were possible predictors of sensitivity to 5‐FU, with cutoff values of 0.6 and 0.4, respectively. The sensitivity of colorectal cancer to 5‐FU may be regulated by DPD, the rate‐limiting enzyme of catabolism, and NT, an important transmembrane transporter of nucleosides.
- 1 June 2003
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 8 (3) , 127-131
5-Fluorouracil and dihydropyrimidine dehydrogenase
Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme of (fluorinated) pyrimidine degradation that plays a significant role in the pharmacokinetics of 5-fluorouracil (5-FU). In addition, a catabolite of 5-FU induces a certain toxicity, and the sensitivity of 5-FU is determined by DPD activity in tumors. DPD is thus important clinically. Drugs have been developed that control variations of the pharmacokinetics of 5-FU by controlling or inhibiting DPD, thereby reducing toxicity and improving sensitivity. These fluorinated pyrimidines with DPD-inhibiting activity, called DPD-inhibitory fluoropyrimidines, contribute to oral therapy with 5-FU for cancer. This paper summarizes the important role of DPD in cancer chemotherapy with 5-FU.
- 1 June 2003
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 8 (3) , 127-131
5-Fluorouracil and dihydropyrimidine dehydrogenase
Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme of (fluorinated) pyrimidine degradation that plays a significant role in the pharmacokinetics of 5-fluorouracil (5-FU). In addition, a catabolite of 5-FU induces a certain toxicity, and the sensitivity of 5-FU is determined by DPD activity in tumors. DPD is thus important clinically. Drugs have been developed that control variations of the pharmacokinetics of 5-FU by controlling or inhibiting DPD, thereby reducing toxicity and improving sensitivity. These fluorinated pyrimidines with DPD-inhibiting activity, called DPD-inhibitory fluoropyrimidines, contribute to oral therapy with 5-FU for cancer. This paper summarizes the important role of DPD in cancer chemotherapy with 5-FU.
- 12 April 2003
- Vol. 23, 583-7
Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination.
Because of the low chemosensitivity of gastric cancer to conventional antitumor agents, the role of adjuvant chemotherapy for patients with advanced gastric cancer is controversial. We have previously proposed the necessity to evaluate the appropriateness of particular adjuvant cancer chemotherapies in individual advanced gastric cancer patients using chemosensitivity testing. In the present study, we compared the chemosensitivity and clinical outcomes of patients with Stages III and IV gastric cancer. A total of 282 patients with advanced gastric cancer were analyzed retrospectively in terms of chemosensitivity as detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and survival outcome after surgery. Patients were split into groups according to Stage III or IV gastric cancer, then categorized into those that received surgery without chemotherapy (surgery-alone), and those that received adjuvant chemotherapy, for which all the evaluable cases were further divided into sensitive and resistant cases as determined by MTT assay. For Stage III gastric cancer patients, the sensitive group had a more favorable survival outcome than the other two groups. For Stage IV gastric cancer patients, the sensitive groups, had a more favorable survival outcome than the other two groups, but only in the absence of peritoneal dissemination. Chemosensitivity testing, based on the MTT assay, was useful in evaluating the appropriate cancer chemotherapy for patients with Stages III/IV gastric cancer without peritoneal dissemination.
- 12 April 2003
- Vol. 23, 583-7
Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination.
Because of the low chemosensitivity of gastric cancer to conventional antitumor agents, the role of adjuvant chemotherapy for patients with advanced gastric cancer is controversial. We have previously proposed the necessity to evaluate the appropriateness of particular adjuvant cancer chemotherapies in individual advanced gastric cancer patients using chemosensitivity testing. In the present study, we compared the chemosensitivity and clinical outcomes of patients with Stages III and IV gastric cancer. A total of 282 patients with advanced gastric cancer were analyzed retrospectively in terms of chemosensitivity as detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and survival outcome after surgery. Patients were split into groups according to Stage III or IV gastric cancer, then categorized into those that received surgery without chemotherapy (surgery-alone), and those that received adjuvant chemotherapy, for which all the evaluable cases were further divided into sensitive and resistant cases as determined by MTT assay. For Stage III gastric cancer patients, the sensitive group had a more favorable survival outcome than the other two groups. For Stage IV gastric cancer patients, the sensitive groups, had a more favorable survival outcome than the other two groups, but only in the absence of peritoneal dissemination. Chemosensitivity testing, based on the MTT assay, was useful in evaluating the appropriate cancer chemotherapy for patients with Stages III/IV gastric cancer without peritoneal dissemination.
- Open Access
- 1 April 2003
- Published by Wiley in Cancer Science
- Vol. 94 (4) , 355-359
Possible chemoresistance‐related genes for gastric cancer detected by cDNA microarray
To identify chemoresistance‐related genes of gastric cancer, we utilized cDNA microarray technology. Thirty‐five gastric cancer specimens surgically resected at our institute between 1998 and 1999 were studied for quantification of expression of 6300 genes by means of oligonucleotide microarray methods, and the results were evaluated in comparison with the chemoresistance of the specimens, which was determined by MTT (tetrazolium‐based 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide) assay. Inhibition rates (IR) were determined for cisplatin (DDP), 5‐fluorouracil (5‐FU), mitomycin C or doxorubicin. IR of 60% or more was regarded as sensitive to each agent, and IR of less than 40% was defined as resistant. Clustering was successfully completed for DDP, resulting in selection of 23 candidates as DDP‐resistance‐related genes, including vascular permeability factor, 2 membrane transporting subunits, and retinoblastoma‐binding protein‐1. In addition, further selection of DDP‐resistance‐related genes was performed according to these criteria: 1) Expression of the gene can be detected in more than 70% of resistant tumors. 2) Expression can be detected in less than 30% of sensitive tumors. 3) Expression in tumors is more than twice that of normal mucosa in more than 50% of specimens. Then, metallothionein‐IG and heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) were identified as candidate DDP‐resistance‐related genes. When known DDP‐resistance‐related genes were analyzed according to the MTT assay result, families of glutathione‐S‐transferase and cydooxygenase‐2 genes were also evaluated as resistance‐related genes. For 5‐FU resistance, dihydropyrimidine dehydrogenase and HB‐EGF‐like growth factor genes were also suggested to be resistance‐related genes. The present study demonstrated that oligonucleotide microarrays can provide information regarding chemoresistance factors in cancer. (Cancer Sci 2003; 94: 355–359)
- 1 April 2003
- Published by Wiley in Cancer Science
- Vol. 94 (4) , 355-359
Open AccessPossible chemoresistance‐related genes for gastric cancer detected by cDNA microarray
To identify chemoresistance‐related genes of gastric cancer, we utilized cDNA microarray technology. Thirty‐five gastric cancer specimens surgically resected at our institute between 1998 and 1999 were studied for quantification of expression of 6300 genes by means of oligonucleotide microarray methods, and the results were evaluated in comparison with the chemoresistance of the specimens, which was determined by MTT (tetrazolium‐based 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide) assay. Inhibition rates (IR) were determined for cisplatin (DDP), 5‐fluorouracil (5‐FU), mitomycin C or doxorubicin. IR of 60% or more was regarded as sensitive to each agent, and IR of less than 40% was defined as resistant. Clustering was successfully completed for DDP, resulting in selection of 23 candidates as DDP‐resistance‐related genes, including vascular permeability factor, 2 membrane transporting subunits, and retinoblastoma‐binding protein‐1. In addition, further selection of DDP‐resistance‐related genes was performed according to these criteria: 1) Expression of the gene can be detected in more than 70% of resistant tumors. 2) Expression can be detected in less than 30% of sensitive tumors. 3) Expression in tumors is more than twice that of normal mucosa in more than 50% of specimens. Then, metallothionein‐IG and heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) were identified as candidate DDP‐resistance‐related genes. When known DDP‐resistance‐related genes were analyzed according to the MTT assay result, families of glutathione‐S‐transferase and cydooxygenase‐2 genes were also evaluated as resistance‐related genes. For 5‐FU resistance, dihydropyrimidine dehydrogenase and HB‐EGF‐like growth factor genes were also suggested to be resistance‐related genes. The present study demonstrated that oligonucleotide microarrays can provide information regarding chemoresistance factors in cancer. (Cancer Sci 2003; 94: 355–359)
- 30 January 2003
- Vol. 22, 3537-40
Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity.
The mode of action of 5-fluorouracil (5-FU) was evaluated in patients with advanced colon cancer treated preoperatively with 5-FU. After obtaining informed consent, 30 patients were randomized into three groups: untreated controls (n = 16), continuous intravenous infusion of 5-FU for 5 days at a dose of 320 mg/m2 (CIV group, n = 6), or bolus intravenous injection of 5-FU for 5 days at the same dose (bolus group, n = 8). Surgically-resected samples were analyzed by 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay to detect sensitivity to 5-FU. Samples were also assayed for thymidylate synthetase (TS) activity, levels of 5-FU RNA (F-RNA), ribonucleotide reductase (RNR) activity, and TS mRNA levels expressed as the ratio of TS mRNA to beta-actin mRNA. While similar levels of TS inhibition were observed in the civ and bolus groups, F-RNA levels were significantly increased in the bolus group. The TS mRNA ratio was significantly higher in the 5-FU-resistant group than 5-FU-sensitive group. In the control group, the 5-FU-sensitive group showed higher RNR enzymatic activity compared to the 5-FU-resistant group. Our results suggested that the method of administration resulted in the induction of different 5-FU metabolic pathways. High TS mRNA and low RNR activity may be concerned with 5-FU-resistance in patients with advanced colon carcinoma.
- 30 January 2003
- Vol. 22, 3537-40
Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity.
The mode of action of 5-fluorouracil (5-FU) was evaluated in patients with advanced colon cancer treated preoperatively with 5-FU. After obtaining informed consent, 30 patients were randomized into three groups: untreated controls (n = 16), continuous intravenous infusion of 5-FU for 5 days at a dose of 320 mg/m2 (CIV group, n = 6), or bolus intravenous injection of 5-FU for 5 days at the same dose (bolus group, n = 8). Surgically-resected samples were analyzed by 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay to detect sensitivity to 5-FU. Samples were also assayed for thymidylate synthetase (TS) activity, levels of 5-FU RNA (F-RNA), ribonucleotide reductase (RNR) activity, and TS mRNA levels expressed as the ratio of TS mRNA to beta-actin mRNA. While similar levels of TS inhibition were observed in the civ and bolus groups, F-RNA levels were significantly increased in the bolus group. The TS mRNA ratio was significantly higher in the 5-FU-resistant group than 5-FU-sensitive group. In the control group, the 5-FU-sensitive group showed higher RNR enzymatic activity compared to the 5-FU-resistant group. Our results suggested that the method of administration resulted in the induction of different 5-FU metabolic pathways. High TS mRNA and low RNR activity may be concerned with 5-FU-resistance in patients with advanced colon carcinoma.
- 1 January 2003
- Published by Springer Nature
- Vol. 161, 231-241
Chemosensitivity Testing - Present and Future in Japan
Radical surgery with extended lymph node dissection is the first and only curative treatment of gastrointestinal cancer. Although the combined cancer chemotherapy has achieved 30%≈50% response rates, a controversy still remains over the significance of the adjuvant cancer chemotherapy after surgery. To break through this limitation, we have introduced the chemosensitivity test to evaluate the appropriate adjuvant cancer chemotherapy for advanced gastrointestinal cancer. Our plural studies indicated that the chemosensitivity test would be useful in evaluating the appropriated adjuvant chemotherapy by increasing survival in the sensitive group. Recently, the molecular targets have been clarified for the conventionally available antitumor agents, e.g., thymidylate synthetase for 5-fluorouracil, ATP-binding cassette transporters for anthracyclines, glutathione-related detoxification for platins, and topoisomerase I for CPT-11, which will be applied for clinical use in evaluating the appropriate cancer chemotherapy. The chemosensitivity test is approved as “advanced clinical medicine” by the Japanese Ministry of Health, Welfare, and Labor in five institutes at present. Because complete dissection and chemosensitivity test-guided adjuvant chemotherapy will result in a survival benefit for patients with advanced gastrointestinal cancer, this test should be approved as “social insurance” for further wide clinical application.
- 1 January 2003
- Published by Springer Nature
- Vol. 161, 231-241
Chemosensitivity Testing - Present and Future in Japan
Radical surgery with extended lymph node dissection is the first and only curative treatment of gastrointestinal cancer. Although the combined cancer chemotherapy has achieved 30%≈50% response rates, a controversy still remains over the significance of the adjuvant cancer chemotherapy after surgery. To break through this limitation, we have introduced the chemosensitivity test to evaluate the appropriate adjuvant cancer chemotherapy for advanced gastrointestinal cancer. Our plural studies indicated that the chemosensitivity test would be useful in evaluating the appropriated adjuvant chemotherapy by increasing survival in the sensitive group. Recently, the molecular targets have been clarified for the conventionally available antitumor agents, e.g., thymidylate synthetase for 5-fluorouracil, ATP-binding cassette transporters for anthracyclines, glutathione-related detoxification for platins, and topoisomerase I for CPT-11, which will be applied for clinical use in evaluating the appropriate cancer chemotherapy. The chemosensitivity test is approved as “advanced clinical medicine” by the Japanese Ministry of Health, Welfare, and Labor in five institutes at present. Because complete dissection and chemosensitivity test-guided adjuvant chemotherapy will result in a survival benefit for patients with advanced gastrointestinal cancer, this test should be approved as “social insurance” for further wide clinical application.
- 1 October 2001
- Published by Springer Nature in Breast Cancer
- Vol. 8 (4) , 333-338
Resistant mechanisms of anthracyclines — pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues
Juliano and Ling initially reported the expression of a 170 kDa glycoprotein in the membrane of Chinese hamster ovarian cells in 1976, and named this glycoprotein P-glycoprotein (P-gp) based on its predicted role of causing “permeability” of the cell membrane. After much research on anthracycline-resistance, this P-gp was finally characterized as a multidrug-resistant protein coded by themdrl gene. Multidrug resistance associated protein (MRP) was initially cloned from H69AR, a human small cell-lung carcinoma cell line which is resistant to doxorubicin (DXR) but does not express P-gp. MRP also excretes substrates through the cell membrane using energy from ATP catabolism. The substrate of MRP is conjugated with glutathione before active efflux from cell membrane. Recently, membrane transporter proteins were re-categorized as members of “ATP-Binding Cassette transporter” (ABC-transporter) superfamily, as shown at http://www.med.rug.nl/mdl/humanabc. htm and http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html. A total of ABC transporters have been defined, and MDR1 and multidrug resistance associated protein 1 (MRP1) were reclassified as ABCB1 and ABCC1, respectively. Their associated superfamilies include 11 and 13 other protein, in addition to ABCB and ABCC, respectively. Lung resistance-related protein (LRP) is not a member of the superfamily of ABC transporter proteins, because it shows nuclear membrane expression and transports substrate between nucleus and cytoplasm. LRP was initially cloned from a non-small cell lung carcinoma cell line, SW1573/2R120 which is resistant to DXR, vincristine, etoposide and gramicidin D and does not express Pgp. The mechanisms of resistance remains unclear, and why some resistant cell lines express P-gp and others express MRP and/or LRP is likewise unclear.
- 1 October 2001
- Published by Springer Nature in Breast Cancer
- Vol. 8 (4) , 333-338
Resistant mechanisms of anthracyclines — pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues
Juliano and Ling initially reported the expression of a 170 kDa glycoprotein in the membrane of Chinese hamster ovarian cells in 1976, and named this glycoprotein P-glycoprotein (P-gp) based on its predicted role of causing “permeability” of the cell membrane. After much research on anthracycline-resistance, this P-gp was finally characterized as a multidrug-resistant protein coded by themdrl gene. Multidrug resistance associated protein (MRP) was initially cloned from H69AR, a human small cell-lung carcinoma cell line which is resistant to doxorubicin (DXR) but does not express P-gp. MRP also excretes substrates through the cell membrane using energy from ATP catabolism. The substrate of MRP is conjugated with glutathione before active efflux from cell membrane. Recently, membrane transporter proteins were re-categorized as members of “ATP-Binding Cassette transporter” (ABC-transporter) superfamily, as shown at http://www.med.rug.nl/mdl/humanabc. htm and http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html. A total of ABC transporters have been defined, and MDR1 and multidrug resistance associated protein 1 (MRP1) were reclassified as ABCB1 and ABCC1, respectively. Their associated superfamilies include 11 and 13 other protein, in addition to ABCB and ABCC, respectively. Lung resistance-related protein (LRP) is not a member of the superfamily of ABC transporter proteins, because it shows nuclear membrane expression and transports substrate between nucleus and cytoplasm. LRP was initially cloned from a non-small cell lung carcinoma cell line, SW1573/2R120 which is resistant to DXR, vincristine, etoposide and gramicidin D and does not express Pgp. The mechanisms of resistance remains unclear, and why some resistant cell lines express P-gp and others express MRP and/or LRP is likewise unclear.